Ignite Creation Date:
2025-12-24 @ 3:17 PM
Ignite Modification Date:
2026-05-05 @ 5:55 PM
Study NCT ID:
NCT02406092
Status:
COMPLETED
Last Update Posted:
2024-11-21
First Post:
2015-03-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Sponsor:
Hoffmann-La Roche
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-Hodgkin Lymphoma | View |
Keywords: